- In April 2023, Bristol Myers Squibb and Pfizer Inc., co-developers of the leading anticoagulant Eliquis (apixaban), announced the expansion of their real-world evidence program to further evaluate the safety and efficacy of Eliquis across broader patient populations, including those with multiple comorbidities. This initiative emphasizes the companies' commitment to evidence-based practice and supports the growing global adoption of direct oral anticoagulants (DOACs) for thrombosis prevention and treatment
- In March 2023, Daiichi Sankyo launched a new clinical trial for its novel oral Factor XIa inhibitor, asundexian, aimed at reducing bleeding risk while maintaining thrombotic protection. This development signals a potential shift toward the next generation of anticoagulants that target clotting factors with greater selectivity, reflecting the industry’s focus on improving patient safety and long-term treatment adherence
- In March 2023, Sanofi entered into a strategic collaboration with Innate Pharma to investigate combination therapies that include anti-thrombotic and immunomodulatory agents for patients with cancer-associated thrombosis. This partnership underscores the growing recognition of thromboembolism as a critical complication in oncology and highlights the trend of integrating thrombosis care within broader treatment paradigms
- In February 2023, Boehringer Ingelheim reported positive Phase III trial results for idarucizumab, a reversal agent for its anticoagulant dabigatran (Pradaxa). The findings reinforced the drug’s safety profile in emergency bleeding scenarios, strengthening its clinical value and supporting regulatory submissions for broader global market access
- In January 2023, Janssen Pharmaceuticals, a Johnson & Johnson company, announced the global expansion of its real-world surveillance program for rivaroxaban (Xarelto), focusing on stroke prevention in atrial fibrillation patients in Asia-Pacific and Latin America. This move reflects Janssen's dedication to evidence-driven insights, especially in emerging markets with rising cardiovascular burdens, and supports broader access to safe and effective thrombosis therapies
